Cancer Letters
Volume 206, Issue 2 , Pages 169-180 , 8 April 2004

Ceramide synthesis and metabolism as a target for cancer therapy

  • C.Patrick Reynolds

      Affiliations

    • Division of Hematology-Oncology MS 57, Children's Hospital of Los Angeles, The University of Southern California Keck School of Medicine, 4650 Sunset Blvd., Los Angeles, CA 90054-0700, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-323-669-5646; fax: +1-323-664-9226/9455
    • ,
  • Barry J. Maurer

      Affiliations

    • Division of Hematology-Oncology MS 57, Children's Hospital of Los Angeles, The University of Southern California Keck School of Medicine, 4650 Sunset Blvd., Los Angeles, CA 90054-0700, USA
    • ,
  • Richard N. Kolesnick

      Affiliations

    • Laboratory of Signal Transduction, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA

Received 28 July 2003 ,Accepted 14 August 2003.

References 

  1. Kolesnick RN. Sphingomyelin and derivatives as cellular signals. (Review) (328 refs). Prog. Lipid Res. 1991;30:1–38
  2. Kolesnick RN. 1,2-Diacylglycerols but not phorbol esters stimulate sphingomyelin hydrolysis in GH3 pituitary cells. J. Biol. Chem. 1987;262:16759–16762
  3. Kolesnick RN, Clegg S. 1,2-Diacylglycerols, but not phorbol esters, activate a potential inhibitory pathway for protein kinase C in GH3 pituitary cells. Evidence for involvement of a sphingomyelinase. J. Biol. Chem. 1988;263:6534–6537
  4. Kolesnick RN. Sphingomyelinase action inhibits phorbol ester-induced differentiation of human promyelocytic leukemic (HL-60) cells. J. Biol. Chem. 1989;264:7617–7623
  5. Okazaki T, Bell RM, Hannun YA. Sphingomyelin turnover induced by vitamin D3 in HL-60 cells. Role in cell differentiation. J. Biol. Chem. 1989;264:19076–19080
  6. Okazaki T, Bielawska A, Bell RM, Hannun YA. Role of ceramide as a lipid mediator of 1 alpha, 25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J. Biol. Chem. 1990;265:15823–15831
  7. Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: from modular to integrative signaling. (Review) (144 refs). Biochemistry. 2001;40:4893–4903
  8. Mathias S, Pena LA, Kolesnick RN. Signal transduction of stress via ceramide (Review) (303 refs). Biochem. J. 1998;335:465–480
  9. Grassme H, Schwarz H, Gulbins E. Molecular mechanisms of ceramide-mediated CD95 clustering. Biochem. Biophys. Res. Commun. 2001;284:1016–1030
  10. Schissel SL, Keesler GA, Schuchman EH, Williams KJ, Tabas I. The cellular trafficking and zinc dependence of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J. Biol. Chem. 1998;273:18250–18259
  11. Schissel SL, Jiang S, Tweedie-Hardman J, Jeong T, Camejo EH, Najib J, et al.  Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 1998;273:2738–2746
  12. Liu P, Anderson RG. Compartmentalized production of ceramide at the cell surface. J. Biol. Chem. 1995;270:27179–27185
  13. Kirschnek S, Paris F, Weller M, Grassme H, Ferlinz K, Riehle A, et al.  CD95-mediated apoptosis in vivo involves acid sphingomyelinase. J. Biol. Chem. 2000;275:27316–27323
  14. Grassme H, Jendrossek V, Bock J, Riehle A, Gulbins E. Ceramide-rich membrane rafts mediate CD40 clustering. J. Immunol. 2002;168:298–307
  15. Segui B, Bezombes C, Uro-Coste E, Medin JA, Andrieu-Abadie N, Auge N, et al.  Stress-induced apoptosis is not mediated by endolysosomal ceramide. Fed. Am. Soc. Exp. Biol. J. 2000;14:36–47
  16. Gulbins E, Grassme H. Ceramide and cell death receptor clustering. Biochim. Biophys. Acta. 2002;1585:139–145
  17. Grassme H, Schwarz H, Gulbins E. Molecular mechanisms of ceramide-mediated CD95 clustering. Biochem. Biophys. Res. Commun. 2001;284:1016–1030
  18. Gulbins E. Regulation of death receptor signaling and apoptosis by ceramide. Pharmacol. Res. 2003;47:393–399
  19. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M, et al.  Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 1996;86:189–199
  20. Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med. 1994;180:525–535
  21. Jaffrezou JP, Bruno AP, Moisand A, Levade T, Laurent G. Activation of a nuclear sphingomyelinase in radiation-induced apoptosis. Fed. Am. Soc. Exp. Biol. J. 2001;15:123–133
  22. Horinouchi K, Erlich S, Perl DP, Ferlinz K, Bisgaier CL, Sandhoff K. Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease. Nat. Genet. 1995;10:288–293
  23. Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J. Biol. Chem. 1998;273:11313–11320
  24. Jayadev S, Linardic CM, Hannun YY. Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha. J. Biol. Chem. 1994;269:5757–5763
  25. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA. 1998;95:681–686
  26. O'Brien NW, Gellings NM, Guo M, Barlow SB, Glembotski CC, Sabbadini RA. Factor associated with neutral sphingomyelinase activation and its role in cardiac cell death. Circ. Res. 2003;92:589–591
  27. Brann AB, Tcherpakov M, Williams IM, Futerman AH, Fainzilber M. Nerve growth factor-induced p75-mediated death of cultured hippocampal neurons is age-dependent and transduced through ceramide generated by neutral sphingomyelinase. J. Biol. Chem. 2002;277:9812–9818
  28. Takeda Y, Tashima M, Takahashi A, Uchiyama T, Okazaki T. Ceramide generation in nitric oxide-induced apoptosis. Activation of magnesium-dependent neutral sphingomyelinase via caspase-3. J. Biol. Chem. 1999;274:10654–10660
  29. Chatterjee S. Neutral sphingomyelinase: past, present and future. Chem. Phys. Lipids. 1999;102:79–96
  30. Tonnetti L, Veri MC, Bonvini E, D'Adamio L. A role for neutral sphingomyelinase-mediated ceramide production in T cell receptor-induced apoptosis and mitogen-activated protein kinase-mediated signal transduction. J. Exp. Med. 1999;189:1581–1589
  31. Kilkus J, Goswami R, Testai FD, Dawson G. Ceramide in rafts detergent-insoluble fraction mediates cell death in neurotumor cell lines. J. Neurosci. Res. 2003;72:65–75
  32. Tomiuk S, Hofmann K, Nix M, Zumbansen M, Stoffel W. Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling?. Proc. Natl. Acad. Sci. USA. 1998;95:3638–3643
  33. Sawai H, Domae N, Nagan N, Hannun YA. Function of the cloned putative neutral sphingomyelinase as lyso-platelet activating factor-phospholipase C. J. Biol. Chem. 1999;274:38131–38139
  34. Hofmann K, Tomiuk S, Wolff G, Stoffel W. Cloning and characterization of the mammalian brain-specific. Mg2+-dependent neutral sphingomyelinase. Proc. Natl. Acad. Sci. USA. 2000;97:5895–5900
  35. Marchesini N, Luberto C, Hannun YA. Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J. Biol. Chem. 2003;278:13775–13783
  36. Liu B, Hassler DF, Smith GK, Weaver K, Hannun YA. Purification and characterization of a membrane bound neutral pH optimum magnesium-dependent and phosphatidylserine-stimulated sphingomyelinase from rat brain. J. Biol. Chem. 1998;273:34472–34479
  37. Bernardo K, Krut O, Wiegmann K, Kreder D, Micheli M, Schafer R. Purification and characterization of a magnesium-dependent neutral sphingomyelinase from bovine brain. J. Biol. Chem. 2000;275:7641–7647
  38. Ogretmen B, Pettus BJ, Rossi MJ, Wood R, Usta J, Szulc Z, et al.  Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J. Biol. Chem. 2002;277:12960–12969
  39. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 1995;82:405–414
  40. Liao WC, Haimovitz-Friedman A, Persaud RS, McLoughlin M, Ehleiter D, et al.  Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase. J. Biol. Chem. 1999;274:17908–17917
  41. Li CM, Park JH, Simonaro CM, He X, Gordon RE, Friedman AH, et al.  Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. (erratum appears in Genomics 2002 Jun;79(6):890 Note: Hepbiloikler Stefan corrected to Hepbildikler Stefan). Genomics. 2002;79:218–224
  42. Kohama T, Olivera A, Edsall L, Nagiec MM, Dickson R, Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J. Biol. Chem. 1998;273:23722–23728
  43. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, et al.  Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem. 2000;275:19513–19520
  44. Abe A, Shayman JA. Purification and characterization of 1-O-acylceramide synthase, a novel phospholipase A2 with transacylase activity. J. Biol. Chem. 1998;273:8467–8474
  45. Abe A, Shayman JA, Radin NS. A novel enzyme that catalyzes the esterification of N-acetylsphingosine. J. Biol. Chem. 1996;271:14383–14389
  46. Okabe H, Kishimoto Y. In vivo metabolism of ceramides in rat brain. Fatty acid replacement and esterification of ceramide. J. Biol. Chem. 1977;252:7068–7073
  47. Taniyama Y, Shibata S, Kita S, Horikoshi K, Fuse H, Shirafuji H, et al.  Cloning and expression of a novel lysophospholipase which structurally resembles lecithin cholesterol acyltransferase. Biochem. Biophys. Res. Commun. 1999;257:50–56
  48. Hiraoka M, Abe A, Shayman JA. Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase. J. Biol. Chem. 2002;277:10090–10099
  49. Tepper AD, Diks SH, van Blitterswijk WJ, Borst J. Glucosylceramide synthase does not attenuate the ceramide pool accumulating during apoptosis induced by CD95 or anti-cancer regimens. J. Biol. Chem. 2000;275:34810–34817
  50. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J. Clin. Invest. 2002;1:3–8
  51. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381:800–803
  52. Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature. 1993;365:557–560
  53. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids-receptor revelations. (Review) (53 refs). Science. 2001;294:1875–1878
  54. Lozano J, Berra E, Muncio MM, Diaz-Meco MT, Dominguez I, Sanz L, et al. Protein kinase C zeta isoform is critical for kappa B-dependent promoter activation by sphingomyelinase. J. Biol. Chem. 1994;269:19200–19202
  55. Leitges M, Sanz L, Martin P, Duran A, Braun U, Garcia JF, et al.  Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway. Mol. Cell. 2001;8:771–780
  56. Diaz-Meco MT, Berra E, Muncio MM, Sanz L, Lozano J, et al.  A dominant negative protein kinase C zeta subspecies blocks NF-kappa B activation. Mol. Cell Biol. 1993;13:4770–4775
  57. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism-a strategy for overcoming drug resistance. (Review) (150 refs). J. Natl Cancer Inst. 2001;93:347–357
  58. el Bawab S, Roddy P, Qian T, Bielawska A, Lemasters JJ, Hannun YA. Molecular cloning and characterization of a human mitochondrial ceramidase. J. Biol. Chem. 2000;275:21508–21513
  59. Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA, et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 2001;61:1233–1240
  60. Liu YY, Han TY, Giuliano AE, Hansen N, Cabot MC. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem. 2000;275:7138–7143
  61. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl Cancer Inst. 2000;92:1897–1909
  62. Banno Y, Kato M, Hara A, Nozawa Y. Evidence for the presence of multiple forms of Sph kinase in human platelets. Biochem. J. 1998;335:301–304
  63. Edsall LC, Van Brocklyn JR, Cuvillier O, Kleuser B, Spiegel S. N,N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry. 1998;37:12892–12898
  64. Schwartz GK, Ward D, Saltz L, Casper ES, Spiess T, Mullen E, et al.  A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin. Cancer Res. 1997;3:537–543
  65. Potten CS. A comprehensive study of the radiobiological response of the murine (BDF1) small intestine(Review) (106 refs). Int. J. Radiat. Biol. 1990;58:925–973
  66. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. (comment). Science. 2001;293:293–297
  67. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, et al. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res. 1995;55:853–861
  68. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. N-(4-hydroxyphenyl)retinamide increases ceramide and reactive oxygen species and induces mixed apoptosis/necrosis in neuroblastoma cell lines. J. Natl Cancer Inst. 1999;91:1138–1146
  69. Sani BP, Shealy YF, Hill DL. N-(4-hydroxyphenyl)retinamide: interactions with retinoid- binding proteins/receptors. Carcinogenesis. 1995;16:2531–2534
  70. Sheikh MS, Shao ZM, Li XS, Ordonez JV, Conley BA, Wu S, et al. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis. 1995;16:2477–2486
  71. Delia D, Aiello A, Meroni L, Nicolini M, Reed JC, Pierotti MA. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis. 1997;18:943–948
  72. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4- hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J. Natl Cancer Inst. 1997;89:1191–1198
  73. Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res. 1998;58:5396–5405
  74. O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia. 2002;16:902–910
  75. Batra S, Maurer BJ, Reynold CP. Fenretinide cytotoxicity in Ewing's sarcoma (ES) and primitive neuroectodermal (PNET) cell lines is blunted by hypoxia but synergistically enhanced by safingol. Proc. Am. Assoc. Cancer Res. 2002;43
  76. Wang H, Maurer BJ, Reynolds CP, Cabot MC. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res. 2001;61:5102–5105
  77. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. (Review) (283 refs). Hematol. Oncol. Clin. North Am. 2001;15:867–910
  78. Villablanca JG, Ames MM, Reid JM, Bagniewski PG, Krailo M, Reynolds CP. Phase I trial of oral N-(4-hydroxyphenyl)retinamide (4-HPR) in children with resistant/recurrent solid tumors: a Children's Cancer Group study (CCG 09709). Proc. Am. Soc. Clin. Oncol. 2002;21: Ref. type: Abstract
  79. Jasti BR, Lo Ruso PM, Parchment RE, Wozniak AJ, Flaherty LE, Shields AF, et al.  Phase I clinical trial of fenretinide (NSC 374551) in advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 2001;20(122A): Ref. type: Abstract
  80. Reynolds CP, Wang Y, Melton LJ, Einhorn PA, Slamon DJ, Maurer BJ. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med. Pediatr. Oncol. 2000;35:597–602
  81. Garzotto M, Haimovitz-Friedman A, Liao WC, White-Jones M, Huryk R, Heston WD, et al.  Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res. 1999;59:5194–5201
  82. Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J, Weichselbaum RR. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res. 1997;57:1270–1275
  83. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M, et al.  Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 1996;86:189–199
  84. Chmura SJ, Nodzenski E, Kharbanda S, Pandey P, Quintans J, Kufe DW, et al. Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol. Pharmacol. 2000;57:792–796
  85. Kimura K, Markowski M, Edsall LC, Spiegel S, Gelmann EP. Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells. Cell Death Differ. 2003;10:240–248
  86. Lin X, Fuks Z, Kolesnick R. Ceramide mediates radiation-induced death of endothelium. Crit. Care Med. 2000;28:N87–N93
  87. Chmura SJ, Mauceri HJ, Advani S, Heimann R, Beckett MA, Nodzenski E, et al.  Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res. 1997;57:4340–4347
  88. Nava VE, Cuvillier O, Edsall LC, Kimura K, Milstien S, Gelmann EP, et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res. 2000;60:4468–4474
  89. Rodriguez-Lafrasse C, Alphonse G, Aloy MT, Ardail D, Gerard JP, Louisot P, et al. Increasing endogenous ceramide using inhibitors of sphingolipid metabolism maximizes ionizing radiation-induced mitochondrial injury and apoptotic cell killing. Int. J. Cancer. 2002;101:589–598
  90. Wang H, Giuliano AE, Cabot MC. Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells. Mol. Cancer Ther. 2002;1:719–726
  91. Goulding CW, Giuliano AE, Cabot MC. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. Cancer Lett. 2000;149:143–151
  92. Abe A, Radin NS, Shayman JA, Wotring LL, Zipkin RE, Sivakumar R. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J. Lipid Res. 1995;36:611–621
  93. Lee L, Abe A, Shayman JA. Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 1999;274:14662–14669
  94. Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 1994;269:8362–8365

PII: S0304-3835(03)00636-0

doi: 10.1016/j.canlet.2003.08.034

Cancer Letters
Volume 206, Issue 2 , Pages 169-180 , 8 April 2004

Article Tools

* Image Usage & Resolution